Ropivacaine is an aminoamide local anesthetic drug marketed by AstraZeneca under the trade name Naropin. It exists as a racemate of its S- and R-enantiomers, although the marketed form is supplied only as the purified S-enantiomer.
Ropivacaine is indicated in adult patients for the induction of regional or local anesthesia for surgery or acute pain management.
Anesthesia, Critical Care and Pain Medicine - University of Parma, Parma, PR, Italy
Rush Oak Park Hospital, Oak Park, Illinois, United States
Department of anaesthesiology, Bispebjerg Hospital, Copenhagen, Denmark
Istituto Ortopedico G. Pini, Milan, Milano, Italy
University of Alabama at Birmingham, Birmingham, Alabama, United States
Nationwide Children's Hospital, Columbus, Ohio, United States
Golden Jubilee National Hospital, Clydebank, West Dunbartonshire, United Kingdom
Gentofte Hospital, Copenhagen, Denmark
Département anesthésie-réanimation, Paris, France
Golden Jubilee National Hospital, Clydebank, West Dunbartonshire, United Kingdom
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.